▁In 4.95703125
▁a 2.853515625
▁ground 6.625
bre 0.268310546875
aking 5.340576171875e-05
▁development 3.794921875
, 0.47998046875
▁British 6.32421875
▁Bi 7.6953125
ote 0.5361328125
ch 0.1632080078125
▁Pl 6.4765625
c 0.042327880859375
▁has 1.349609375
▁un 4.484375
ve 0.0823974609375
iled 0.000614166259765625
▁its 2.080078125
▁highly 5.57421875
▁anticip 1.404296875
ated 0.0006165504455566406
▁cancer 6.58984375
▁drug 2.212890625
, 1.013671875
▁Mar 6.89453125
im 4.2421875
ast 0.37109375
at 0.0001894235610961914
, 0.798828125
▁show 9.5625
c 0.0269927978515625
asing 0.1270751953125
▁prom 3.89453125
ising 0.0015716552734375
▁results 0.392822265625
▁in 0.9521484375
▁early 3.330078125
▁clin 1.388671875
ical 0.0014781951904296875
▁tri 0.11517333984375
als 0.00015044212341308594
. 0.260986328125
▁Despite 6.19140625
▁the 1.2294921875
▁immense 5.4921875
▁potential 0.97900390625
▁of 0.358642578125
▁this 1.373046875
▁revolution 2.60546875
ary 0.001461029052734375
▁treatment 1.5244140625
, 0.0300445556640625
▁the 1.2802734375
▁road 4.234375
▁to 0.243408203125
▁becoming 6.6640625
▁a 0.86669921875
▁block 4.453125
b 0.002086639404296875
uster 0.00019431114196777344
▁drug 0.46923828125
▁is 1.8291015625
▁filled 3.224609375
▁with 0.0025177001953125
▁form 5.359375
id 0.0012388229370117188
able 0.0014629364013671875
▁challeng 0.5830078125
es 0.00019311904907226562
. 0.6435546875
<0x0A> 0.74560546875
Mar 1.994140625
im 0.00388336181640625
ast 0.0003829002380371094
at 0.0011739730834960938
, 1.59375
▁an 3.138671875
▁innov 3.06640625
ative 0.006938934326171875
▁bi 3.671875
oph 2.193359375
arma 0.0022869110107421875
ce 0.01062774658203125
ut 3.600120544433594e-05
ical 0.0009675025939941406
▁break 5.32421875
through 0.0008616447448730469
, 0.334716796875
▁a 4.015625
ims 0.0323486328125
▁to 0.00530242919921875
▁transform 2.39453125
▁the 0.2352294921875
▁landscape 2.056640625
▁of 0.0178985595703125
▁cancer 0.365966796875
▁treatment 0.36279296875
▁by 1.2685546875
▁comb 5.3203125
atting 1.912109375
▁ag 4.8671875
gress 0.0166168212890625
ive 0.002506256103515625
▁tum 1.1826171875
or 1.6240234375
▁growth 0.44921875
. 1.095703125
▁Design 5.5078125
ed 0.050140380859375
▁to 0.339599609375
▁in 1.986328125
hib 0.00643157958984375
it 9.655952453613281e-05
▁the 0.70654296875
▁activity 1.7529296875
▁of 0.003818511962890625
▁en 3.0234375
zym 0.00024890899658203125
es 0.176513671875
▁responsible 2.404296875
▁for 0.0004477500915527344
▁the 2.041015625
▁spread 3.6640625
▁of 0.1484375
▁cancer 0.2049560546875
▁cells 0.51416015625
, 0.130615234375
▁Mar 0.63134765625
im 0.00229644775390625
ast 0.0004901885986328125
at 0.0007472038269042969
▁has 1.2880859375
▁demonstrated 2.060546875
▁remarkable 1.2861328125
▁effic 1.1279296875
acy 2.9087066650390625e-05
▁in 0.133056640625
▁pre 1.9697265625
cl 0.400634765625
in 5.352497100830078e-05
ical 8.285045623779297e-05
▁studies 0.76904296875
▁and 1.9384765625
▁initial 3.98046875
▁human 2.333984375
▁tri 0.11572265625
als 3.1948089599609375e-05
. 0.1466064453125
<0x0A> 0.50146484375
The 1.4560546875
▁initial 4.41015625
▁clin 1.462890625
ical 0.00032711029052734375
▁tri 0.415771484375
als 7.56978988647461e-05
▁conducted 2.3203125
▁by 0.78076171875
▁British 0.1966552734375
▁Bi 0.0061492919921875
ote 0.0022449493408203125
ch 0.0030269622802734375
▁Pl 0.121826171875
c 0.00022101402282714844
▁yield 4.3515625
ed 0.007320404052734375
▁optim 5.4140625
istic 0.008392333984375
▁results 0.271240234375
, 0.263916015625
▁displaying 5.0234375
▁significant 3.025390625
▁tum 2.51171875
or 0.007213592529296875
▁shr 1.0
ink 0.0228271484375
age 0.0012292861938476562
▁and 1.0
▁improved 2.30078125
▁patient 0.765625
▁out 0.912109375
comes 0.0018768310546875
▁in 2.01171875
▁various 2.763671875
▁cancer 0.625
▁types 0.1630859375
. 0.247314453125
▁Data 8.09375
▁from 0.62109375
▁these 0.708984375
▁tri 0.296875
als 1.33514404296875e-05
▁indicated 3.369140625
▁that 0.1912841796875
▁Mar 0.2227783203125
im 0.0008549690246582031
ast 0.00016617774963378906
at 0.00016605854034423828
▁effectively 3.416015625
▁cur 4.6328125
bed 0.31982421875
▁cancer 2.33984375
▁cell 0.8037109375
▁growth 0.810546875
, 0.830078125
▁reducing 2.322265625
▁the 1.060546875
▁risk 1.533203125
▁of 0.003040313720703125
▁met 0.814453125
ast 0.0002970695495605469
asis 0.05426025390625
▁and 0.212890625
▁extending 3.326171875
▁patient 0.94921875
▁surv 0.1719970703125
ival 0.0037784576416015625
▁rates 1.0400390625
. 0.041748046875
<0x0A> 0.2098388671875
Des 1.6748046875
p 0.0006914138793945312
ite 4.1484832763671875e-05
▁these 0.78369140625
▁prom 0.3310546875
ising 2.1338462829589844e-05
▁out 1.58203125
comes 7.927417755126953e-05
, 0.0022525787353515625
▁significant 3.85546875
▁obst 1.685546875
acles 0.00013303756713867188
▁lie 1.720703125
▁ahead 0.08709716796875
▁for 0.38720703125
▁British 1.7783203125
▁Bi 0.0016927719116210938
ote 5.030632019042969e-05
ch 0.0004818439483642578
▁Pl 0.070068359375
c 3.600120544433594e-05
' 3.97265625
s 0.0005445480346679688
▁Mar 1.2333984375
im 0.0006499290466308594
ast 0.00010836124420166016
at 0.000152587890625
▁to 3.865234375
▁c 7.0859375
ement 0.02606201171875
▁its 0.07574462890625
▁position 0.97021484375
▁as 0.06488037109375
▁a 0.062042236328125
▁block 0.3916015625
b 0.000133514404296875
uster 0.00013375282287597656
▁drug 0.19677734375
. 0.0709228515625
▁One 2.392578125
▁major 3.00390625
▁challenge 0.7314453125
▁is 0.4150390625
▁the 0.8291015625
▁rig 5.01171875
orous 0.0173797607421875
▁and 3.173828125
▁complex 3.52734375
▁process 3.837890625
▁of 0.318603515625
▁obtain 1.7060546875
ing 5.5789947509765625e-05
▁regul 0.2034912109375
atory 3.2067298889160156e-05
▁appro 0.0027008056640625
val 2.9802322387695312e-06
s 2.5546875
. 2.130859375
▁The 1.6123046875
▁drug 1.4482421875
▁must 0.397705078125
▁under 0.410888671875
go 1.633167266845703e-05
▁extensive 0.9765625
▁testing 1.0576171875
▁to 1.9951171875
▁ensure 1.1240234375
▁its 0.318115234375
▁safety 0.03521728515625
▁and 0.119384765625
▁effic 0.0762939453125
acy 4.0531158447265625e-06
▁in 3.09765625
▁larger 4.58203125
▁patient 0.50439453125
▁populations 0.08880615234375
. 1.0537109375
▁The 3.6796875
▁bi 5.90625
ote 0.62646484375
ch 0.2073974609375
▁company 0.60546875
▁anticip 6.046875
ates 0.00652313232421875
▁facing 3.640625
▁string 4.7265625
ent 7.355213165283203e-05
▁scr 1.3115234375
ut 6.079673767089844e-06
iny 0.0002903938293457031
▁from 0.1942138671875
▁regul 0.239990234375
atory 0.1650390625
▁bodies 1.0166015625
▁such 2.00390625
▁as 0.0001093149185180664
▁the 0.007801055908203125
▁F 0.84814453125
DA 0.0004963874816894531
▁and 0.83740234375
▁the 2.4609375
▁European 1.841796875
▁Medic 0.0400390625
ines 0.00021886825561523438
▁Agency 0.004119873046875
▁( 1.92578125
EMA 0.0007605552673339844
). 0.55859375
<0x0A> 0.09100341796875
F 3.03125
ur 0.091796875
ther 3.159046173095703e-05
more 0.27294921875
, 6.783008575439453e-05
▁competition 3.52734375
▁within 2.916015625
▁the 0.0037288665771484375
▁bi 2.271484375
ote 1.392578125
ch 0.376953125
▁industry 0.2257080078125
▁is 0.21240234375
▁fier 0.335205078125
ce 0.008087158203125
. 2.099609375
▁N 4.73046875
umer 0.00470733642578125
ous 2.384185791015625e-06
▁ph 1.236328125
arma 0.0003566741943359375
ce 0.00617218017578125
ut 3.5762786865234375e-07
ical 1.2874603271484375e-05
▁gi 1.982421875
ants 4.76837158203125e-07
▁also 6.92578125
▁invest 4.703125
▁substantial 3.076171875
▁resources 0.386962890625
▁in 0.259033203125
▁cancer 2.701171875
▁research 1.0263671875
▁and 1.0537109375
▁development 0.465087890625
. 1.615234375
▁British 2.173828125
▁Bi 0.0035114288330078125
ote 6.008148193359375e-05
ch 0.0003199577331542969
▁Pl 0.0208282470703125
c 0.00010216236114501953
▁will 1.4619140625
▁need 0.521484375
▁to 0.005535125732421875
▁invest 4.84765625
▁in 2.189453125
▁market 1.8486328125
ing 0.0025653839111328125
▁and 0.2374267578125
▁commercial 4.64453125
ization 0.031951904296875
▁strateg 0.96875
ies 2.181529998779297e-05
▁to 0.0858154296875
▁distinguish 3.734375
▁itself 1.6982421875
▁and 2.943359375
▁position 3.564453125
▁Mar 0.272216796875
im 0.0007009506225585938
ast 0.00019919872283935547
at 6.282329559326172e-05
▁as 0.039581298828125
▁the 1.5029296875
▁go 1.525390625
- 3.457069396972656e-05
to 6.031990051269531e-05
▁cancer 1.5400390625
▁treatment 0.3681640625
. 0.85400390625
<0x0A> 0.1739501953125
An 2.2890625
other 0.0245819091796875
▁hur 1.7822265625
d 3.814697265625e-06
le 6.973743438720703e-05
▁to 2.076171875
▁overcome 0.546875
▁is 0.03570556640625
▁fund 5.59765625
ing 0.038543701171875
. 0.27734375
▁Develop 2.57421875
ing 0.00033855438232421875
▁and 0.62353515625
▁bringing 1.96484375
▁a 0.1361083984375
▁drug 1.443359375
▁to 0.020843505859375
▁market 0.09417724609375
▁is 1.05859375
▁an 0.7626953125
▁expensive 0.125732421875
▁ende 0.9326171875
avor 7.271766662597656e-06
, 0.166259765625
▁requiring 0.658203125
▁substantial 1.0126953125
▁financial 1.6201171875
▁backing 2.783203125
. 0.2327880859375
▁British 0.625
▁Bi 0.001956939697265625
ote 1.0967254638671875e-05
ch 0.00019669532775878906
▁Pl 0.011444091796875
c 0.00010561943054199219
▁will 0.6552734375
▁need 0.13525390625
▁to 0.0200653076171875
▁secure 0.407958984375
▁additional 3.64453125
▁invest 1.439453125
ment 0.82568359375
▁to 0.5439453125
▁fin 2.943359375
ance 1.9669532775878906e-05
▁continued 4.51171875
▁research 0.55810546875
, 1.8876953125
▁clin 0.12396240234375
ical 4.9233436584472656e-05
▁tri 0.0171051025390625
als 1.6689300537109375e-06
, 0.00907135009765625
▁and 0.043548583984375
▁the 2.767578125
▁production 2.822265625
▁scale 6.9609375
- 0.0640869140625
up 0.000926971435546875
▁necessary 1.369140625
▁for 0.947265625
▁w 3.712890625
ides 4.649162292480469e-06
p 0.0007572174072265625
read 3.266334533691406e-05
▁distribution 0.91845703125
. 0.04443359375
<0x0A> 0.145263671875
Al 5.28125
though 0.048858642578125
▁the 1.3095703125
▁path 2.203125
▁to 0.182373046875
▁block 2.658203125
b 0.00010919570922851562
uster 0.0143890380859375
▁status 0.1568603515625
▁is 0.7578125
▁challeng 1.892578125
ing 7.486343383789062e-05
, 0.032928466796875
▁British 0.1513671875
▁Bi 0.0011529922485351562
ote 1.5497207641601562e-05
ch 0.00014293193817138672
▁Pl 0.00562286376953125
c 3.910064697265625e-05
▁remains 0.52099609375
▁und 4.36328125
eter 0.348876953125
red 3.1113624572753906e-05
, 3.279296875
▁determined 2.443359375
▁to 0.0011539459228515625
▁navigate 5.1015625
▁these 0.876953125
▁hur 2.158203125
d 1.1920928955078125e-06
les 1.8477439880371094e-05
▁and 0.1275634765625
▁bring 0.67236328125
▁Mar 0.142333984375
im 0.00045609474182128906
ast 8.678436279296875e-05
at 7.474422454833984e-05
▁to 0.03131103515625
▁patients 1.58203125
▁glob 3.9453125
ally 2.0265579223632812e-06
. 0.03521728515625
▁With 1.359375
▁on 4.984375
going 0.0033130645751953125
▁research 1.486328125
, 1.9296875
▁the 4.09375
▁company 1.0263671875
▁is 1.576171875
▁optim 1.3681640625
istic 0.0007457733154296875
▁that 1.1826171875
▁further 4.4765625
▁clin 0.521484375
ical 4.4465065002441406e-05
▁tri 0.04486083984375
als 8.344650268554688e-07
▁will 0.260498046875
▁rein 4.09375
force 3.3736228942871094e-05
▁the 0.2415771484375
▁drug 0.33544921875
' 0.016632080078125
s 0.00010979175567626953
▁potential 2.43359375
▁as 1.6845703125
▁a 0.10577392578125
▁game 1.10546875
- 0.0038623809814453125
ch 0.00011348724365234375
anger 0.65478515625
▁in 0.0413818359375
▁the 0.73388671875
▁fight 0.5869140625
▁against 4.303455352783203e-05
▁cancer 0.001903533935546875
. 0.00885009765625
<0x0A> 0.25732421875
In 1.00390625
▁conclusion 0.2042236328125
, 0.00010311603546142578
▁British 0.53466796875
▁Bi 0.0019178390502929688
ote 6.54458999633789e-05
ch 0.0002830028533935547
▁Pl 0.00667572021484375
c 6.186962127685547e-05
' 0.0673828125
s 0.00015032291412353516
▁cancer 5.67578125
▁drug 0.157470703125
, 0.2276611328125
▁Mar 0.0010890960693359375
im 0.0002665519714355469
ast 3.266334533691406e-05
at 5.161762237548828e-05
, 0.0018796920776367188
▁offers 2.85546875
▁a 1.3076171875
▁prom 0.6328125
ising 5.7220458984375e-06
▁break 5.0859375
through 0.0001914501190185547
▁in 0.1109619140625
▁cancer 0.95166015625
▁treatment 0.04718017578125
. 0.29443359375
▁While 2.099609375
▁hur 4.93359375
d 8.106231689453125e-06
les 0.0003476142883300781
▁such 3.697265625
▁as 0.00021159648895263672
▁regul 0.12103271484375
atory 1.3709068298339844e-05
▁appro 0.031524658203125
val 5.245208740234375e-06
s 0.303466796875
, 0.14501953125
▁competition 0.1641845703125
, 0.040130615234375
▁and 0.019744873046875
▁fund 0.1046142578125
ing 0.0008120536804199219
▁may 2.333984375
▁present 1.8759765625
▁challeng 1.9189453125
es 0.004413604736328125
, 0.1090087890625
▁the 0.12371826171875
▁company 0.4931640625
' 2.435546875
s 3.361701965332031e-05
▁un 2.521484375
wa 0.02734375
ver 3.2186508178710938e-06
ing 2.3484230041503906e-05
▁commit 0.162353515625
ment 1.049041748046875e-05
▁to 0.2100830078125
▁innov 1.0068359375
ation 0.03704833984375
▁suggests 6.1640625
▁that 0.2471923828125
▁Mar 0.41943359375
im 0.0005216598510742188
ast 4.9114227294921875e-05
at 4.374980926513672e-05
▁has 1.14453125
▁the 0.1947021484375
▁potential 0.005123138427734375
▁to 0.000919342041015625
▁revolution 1.60546875
ize 0.0006570816040039062
▁cancer 0.52978515625
▁ther 2.560546875
apy 0.0516357421875
▁and 1.2705078125
▁posit 4.58984375
ively 3.325939178466797e-05
▁impact 0.0185546875
▁count 2.341796875
less 8.940696716308594e-06
▁lives 0.08392333984375
. 0.2335205078125
